| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| D Heuschmann, O Butenandt, M Voge. Left ventricular volume and mass in children on growth hormone therapy compared with untreated children. European journal of pediatrics. vol 155. issue 2. 1996-12-04. PMID:8775217. |
an excess of gh as in acromegaly, causes various problems within the circulatory system including cardiac hypertrophy. |
1996-12-04 |
2023-08-12 |
Not clear |
| H Ohtsuka, I Komiya, T Aizawa, T Yamad. Hypertension in acromegaly: hereditary hypertensive factor produces hypertension by enhancing IGF-I production. Endocrine journal. vol 42. issue 6. 1996-11-14. PMID:8822320. |
the above results suggest that the genetic factor produces hypertension in acromegaly by two ways, by increasing na and enhancing igf-i production by gh. |
1996-11-14 |
2023-08-12 |
Not clear |
| R Ochoa, E Fonseca, M Mercado, R E Galván, M Hernández, A Zárat. The magnitude of growth hormone elevation is related with the proportion of monomeric form in acromegaly. Archives of medical research. vol 26 Spec No. 1996-10-24. PMID:8845645. |
sera from 11 patients with active acromegaly were subjected to gel chromatography on sephadex g-100 column and fractions were collected for ria to measure gh. |
1996-10-24 |
2023-08-12 |
Not clear |
| E Ciccarelli, S Grottoli, P Razzore, L Gianotti, E Arvat, R Deghenghi, G Camanni, E Ghig. Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients. Clinical endocrinology. vol 44. issue 1. 1996-09-11. PMID:8706295. |
we have therefore evaluated the effect of hexarelin on prl and gh secretion in patients with active acromegaly or pathological hyperprolactinaemia. |
1996-09-11 |
2023-08-12 |
Not clear |
| S J Padayatty, E J Perrins, P E Belchet. Octreotide treatment increases exercise capacity in patients with acromegaly. European journal of endocrinology. vol 134. issue 5. 1996-08-08. PMID:8664974. |
we conclude that the decrease in gh and igf-i following octreotide treatment of acromegaly is accompanied by decreased heart rate and increased exercise capacity despite an unchanged ejection fraction. |
1996-08-08 |
2023-08-12 |
Not clear |
| T Ishizuka, H Morita, T Mune, H Daidoh, J Hanafusa, M Yamamoto, T Shibata, K Yasud. Growth hormone secretion in human acromegalic pituitary adenomas: cyclic adenosine monophosphate and protein kinase C responses. Metabolism: clinical and experimental. vol 45. issue 2. 1996-04-18. PMID:8596491. |
we examined the effect of phorbol ester on growth hormone (gh)-releasing hormone (grh)-induced gh secretion and cyclic adenosine monophosphate (camp) production in three pituitary adenomas and thyrotropin-releasing hormone (trh)- and corticotropin-releasing hormone (crh)-induced redistribution of protein kinase c (pkc) from cytosol to membrane in a pituitary adenoma resected from patients with acromegaly. |
1996-04-18 |
2023-08-12 |
human |
| E E Müller, M Rolla, E Ghigo, D Belliti, E Arvat, A Andreoni, A Torsello, V Locatelli, F Camann. Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications. Drugs. vol 50. issue 5. 1996-03-27. PMID:8586028. |
secretion of growth hormone (gh) is excessive in acromegaly, but also in a number of other pathological states such as anorexia nervosa, insulin-dependent diabetes mellitus (iddm), liver cirrhosis, depression, renal failure and gh-insensitivity syndrome. |
1996-03-27 |
2023-08-12 |
Not clear |
| E E Müller, M Rolla, E Ghigo, D Belliti, E Arvat, A Andreoni, A Torsello, V Locatelli, F Camann. Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications. Drugs. vol 50. issue 5. 1996-03-27. PMID:8586028. |
abnormalities in the neuroendocrine control of gh secretion and/or a state of insensitivity to gh contribute to hypersecretion of gh in these states, with the possible exception of acromegaly, which appears to be a primary pituitary disease. |
1996-03-27 |
2023-08-12 |
Not clear |
| E E Müller, M Rolla, E Ghigo, D Belliti, E Arvat, A Andreoni, A Torsello, V Locatelli, F Camann. Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications. Drugs. vol 50. issue 5. 1996-03-27. PMID:8586028. |
this review discusses the involvement of brain catecholamines and acetylcholine in gh hypersecretory states, including anorexia nervosa, acromegaly, iddm, liver cirrhosis, depression, renal failure and gh insensitivity syndrome, with a view to providing a fuller understanding of their pathophysiology and, whenever possible, diagnostic and therapeutic implications. |
1996-03-27 |
2023-08-12 |
Not clear |
| E Wolf, R Wanke, E Schenck, W Hermanns, G Bre. Effects of growth hormone overproduction on grip strength of transgenic mice. European journal of endocrinology. vol 133. issue 6. 1996-02-22. PMID:8548060. |
on the other hand, chronic hypersecretion of gh in active acromegaly may result in outwardly hypertrophied but functionally weaker muscles. |
1996-02-22 |
2023-08-12 |
mouse |
| A K Fløgstad, J Halse, T Haldorsen, I Lancranjan, P Marbach, C Bruns, J Jervel. Sandostatin LAR in acromegalic patients: a dose-range study. The Journal of clinical endocrinology and metabolism. vol 80. issue 12. 1996-01-31. PMID:8530606. |
we have investigated the efficacy and tolerability of sandostatin lar given as a single dose im to patients with active acromegaly who showed good gh suppression during a 2- to 4-week pretreatment period with octreotide given sc. |
1996-01-31 |
2023-08-12 |
Not clear |
| M Semer, A C Faria, M Nery, L R Salgado, M Knoepfelmacher, B L Wajchenberg, B Liberma. Growth hormone pulsatility in active and cured acromegalic subjects. The Journal of clinical endocrinology and metabolism. vol 80. issue 12. 1996-01-31. PMID:8530632. |
we studied gh secretion by cluster analysis, collecting samples every 20 min for 24 h in 44 subjects: 11 patients with active acromegaly; 16 "cured" acromegalics, and 17 normal subjects. |
1996-01-31 |
2023-08-12 |
human |
| M Semer, A C Faria, M Nery, L R Salgado, M Knoepfelmacher, B L Wajchenberg, B Liberma. Growth hormone pulsatility in active and cured acromegalic subjects. The Journal of clinical endocrinology and metabolism. vol 80. issue 12. 1996-01-31. PMID:8530632. |
the purpose of this study was to compare gh secretion between patients with active acromegaly and "cured" patients and between "cured" acromegalic patients and normal controls. |
1996-01-31 |
2023-08-12 |
human |
| N Tsukamoto, T Nagaya, A Kuwayama, K Takano, K Shizume, K Sugita, H Se. Octreotide treatment results in the inhibition of GH gene expression in the adenoma of the patients with acromegaly. Endocrine journal. vol 41. issue 4. 1996-01-29. PMID:8528360. |
octreotide treatment results in the inhibition of gh gene expression in the adenoma of the patients with acromegaly. |
1996-01-29 |
2023-08-12 |
human |
| C M Cuttica, P Sessarego, S Valenti, M R Falivene, M Giusti, G Giordan. Sumatriptan does not stimulate PRL and GH secretion in acromegaly. Minerva endocrinologica. vol 20. issue 2. 1996-01-26. PMID:8531896. |
sumatriptan does not stimulate prl and gh secretion in acromegaly. |
1996-01-26 |
2023-08-12 |
Not clear |
| C M Cuttica, P Sessarego, S Valenti, M R Falivene, M Giusti, G Giordan. Sumatriptan does not stimulate PRL and GH secretion in acromegaly. Minerva endocrinologica. vol 20. issue 2. 1996-01-26. PMID:8531896. |
we studied the effects of sumatriptan, a new 5-ht1d receptor agonist, on prl and gh secretion in active acromegaly. |
1996-01-26 |
2023-08-12 |
Not clear |
| P M Stewart, K F Kane, S E Stewart, I Lancranjan, M C Sheppar. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. The Journal of clinical endocrinology and metabolism. vol 80. issue 11. 1995-12-28. PMID:7593436. |
octreotide (sandostatin) is a synthetic analog of somatostatin, an endogenous gh inhibitory peptide that has been used as an adjunct to surgery and radiotherapy in the treatment of acromegaly. |
1995-12-28 |
2023-08-12 |
Not clear |
| R Lanzi, A C Andreotti, A Caumo, M F Manzoni, M Losa, M E Malighetti, A E Pontirol. Assessment of growth hormone (GH) plasma clearance rate, half-life, and volume of distribution in acromegalic patients: the combined GH-octreotide infusion. The Journal of clinical endocrinology and metabolism. vol 80. issue 11. 1995-12-28. PMID:7593438. |
in acromegaly, high gh levels are primarily attributable to gh hypersecretion, but the contribution of gh clearance is still under debate and is difficult to assess. |
1995-12-28 |
2023-08-12 |
human |
| R Lanzi, A C Andreotti, A Caumo, M F Manzoni, M Losa, M E Malighetti, A E Pontirol. Assessment of growth hormone (GH) plasma clearance rate, half-life, and volume of distribution in acromegalic patients: the combined GH-octreotide infusion. The Journal of clinical endocrinology and metabolism. vol 80. issue 11. 1995-12-28. PMID:7593438. |
our results also indicate that the increased circulating gh levels observed in acromegaly are attributable only to gh overproduction and do not depend on an alteration in the processes of gh distribution or disappearance. |
1995-12-28 |
2023-08-12 |
human |
| A Giustina, E Bresciani, G Bugari, A R Bussi, R Deghenghi, B Imbimbo, G Giustin. Hexarelin, a novel GHRP-6 analog, counteracts the inhibitory effect of hydrocortisone on growth hormone secretion in acromegaly. Endocrine research. vol 21. issue 3. 1995-12-21. PMID:7588427. |
our data show that the gh response to hexarelin in acromegaly is resistant to the inhibitor action of an acute and sustained elevation of serum cortisol levels. |
1995-12-21 |
2023-08-12 |
Not clear |